Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$806.06 USD

806.06
3,599,482

-0.08 (-0.01%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $804.12 -1.94 (-0.24%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q4 Earnings?

AbbVie's (ABBV) Q4 top line is expected to have witnessed a recovery in demand amid improving global economies. However, resurgence of COVID-19 cases is likely to have hurt sales of physician-administered drugs.

Benjamin Rains headshot

Buy Pharma Giant AbbVie Stock Before Q4 Earnings for Dividend and Value?

Let's check out AbbVie to see if investors might want to buy the stock ahead of its fourth quarter fiscal 2020 financial release that's due out before the opening bell on Wednesday, Feb. 3...

Personal Income Increased in December

Personal Income Increased in December

Will Recovery in AbbVie's (ABBV) Earnings Continue in Q4?

Recovery in AbbVie's (ABBV) revenues is likely to have continued in the fourth quarter. Investors focus is likely to be on 2021 guidance when the company reports results in the wake of rising cases.

Mark Vickery headshot

Economic Prints, Q4 Reports Up for Lilly, CAT; J&J Posts Phase-3 Data

With the GameStop (GME) short-squeeze saga continuing, market indexes work to regain their equilibrium.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q4 Earnings, MRK & LLY's Coronavirus Updates

J&J (JNJ) and Novartis (NVS) announce Q4 results. Merck (MRK), AbbVie (ABBV) & Pfizer (PFE) get EU approvals.

Vertex's (VRTX) IND for Type I Diabetes Drug Gets FDA Clearance

Vertex (VRTX) gets FDA clearance for the investigational new drug application of VX-880, for the potential treatment of type I diabetes.

Eli Lilly (LLY) Q4 Earnings Top, COVID-19 Antibody Boosts Sales

Lilly (LLY) beats fourth-quarter estimates for both earnings and sales. Stock up in pre-market trading.

5 Big Pharma/Biotech Stocks Set to Trump Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks including Sanofi (SNY) and Merck (MRK) that are poised to beat fourth-quarter earnings estimates.

Lilly (LLY) Partners Vir/Glaxo for COVID-19 Combo Regimen

Lilly (LLY) collaborates with Vir and Glaxo to develop its COVID-19 therapy, bamlanivimab, in combination with their COVID-19 antibody candidate.

Dr. Reddy's (RDY) Ends Kuwait Study on Avigan for COVID-19

Dr. Reddy's (RDY) and Global Response Aid FZCO terminate the Avigan study conducted in Kuwait, focused on moderate-to-severe COVID patients in a hospital setting.

Regeneron (REGN) COVID-19 Cocktail Effective Against New Variants

Regeneron (REGN) reports research data confirming that antibody REGEN-COV is effective against the SARS-CoV-2 variants.

Is a Surprise Coming for Lilly (LLY) This Earnings Season?

Lilly (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Lilly's (LLY) Bamlanivimab Combo Lowers COVID-19 Hospitalization

Eli Lilly's (LLY) combination of its COVID-19 antibodies bamlanivimab (LY-CoV555) plus etesevimab (LY-CoV016) reduces COVID-19-related hospitalizations and deaths by 70%.

Pfizer (PFE) to Report Q4 Earnings: What's in the Cards?

Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the fourth quarter.

Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

Style Box ETF report for FTCS

Regeneron's (REGN) Performance Strong in 2020: What Lies Ahead?

Regeneron's (REGN) efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive and position it for growth in 2021.

Will Eli Lilly (LLY) Beat Estimates This Earnings Season?

Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) fourth-quarter sales.

Lilly's (LLY) Bamlanivimab Lowers COVID-19 Risk in Nursing Homes

Eli Lilly's (LLY) COVID-19 antibody drug bamlanivimab (LY-CoV555) reduces risk of contracting symptomatic COVID-19 infection by 80% at nursing homes in the United States.

J&J (JNJ) to Get the Ball Rolling for Pharma Q4 Earnings

J&J's (JNJ) Pharma segment is expected to have performed above market while continued procedure stabilization is expected to have benefited the Medical Devices segment in the fourth quarter.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to MRK, AZN, JNJ, GSK Drugs, LLY's New Antibody Deal

Merck (MRK), Glaxo (GSK), AstraZeneca (AZN) and J&J (JNJ) announce FDA approvals.

Adamis (ADMP) Submits Tempol IND for COVID-19, Shares Soar

Adamis (ADMP) submits an investigational new drug (IND) to the FDA for the investigational use of Tempol for the treatment of COVID-19.

Will Sarepta's (SRPT) Overdependence on Exondys 51 Hurt?

Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on Exondys 51 for near-term growth is a concern.

Precision BioSciences' (DTIL) New Lymphoma Drug IND Gets FDA Nod

The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.

Lilly (LLY) Inks Deal With Merus to Discover Cancer Antibodies

Eli Lilly (LLY) signs a deal with Merus to develop novel T-cell re-directing bispecific antibodies. While Merus will lead early-stage development, Loxo Oncology will take care of further development and commercialization.